Compare PRIM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | RYTM |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.8B |
| IPO Year | 2006 | 2017 |
| Metric | PRIM | RYTM |
|---|---|---|
| Price | $86.66 | $108.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $155.20 | $131.14 |
| AVG Volume (30 Days) | ★ 2.1M | 985.9K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 51.66 | 28.34 |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.92 | $55.34 |
| Revenue Next Year | $8.80 | $86.06 |
| P/E Ratio | $279.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.00 | $74.50 |
| 52 Week High | $205.50 | $122.20 |
| Indicator | PRIM | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 60.84 |
| Support Level | $65.00 | $98.30 |
| Resistance Level | $133.04 | $113.03 |
| Average True Range (ATR) | 6.81 | 4.86 |
| MACD | 0.41 | 0.24 |
| Stochastic Oscillator | 49.68 | 63.85 |
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.